U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C33H34N6O6
Molecular Weight 610.6597
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CANDESARTAN CILEXETIL

SMILES

CCOC1=NC2=C(N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5)C(=CC=C2)C(=O)OC(C)OC(=O)OC6CCCCC6

InChI

InChIKey=GHOSNRCGJFBJIB-UHFFFAOYSA-N
InChI=1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)

HIDE SMILES / InChI

Molecular Formula C33H34N6O6
Molecular Weight 610.6597
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including http://www.japsonline.com/admin/php/uploads/290_pdf.pdf

Candesartan is classified as an angiotensin II receptor type 1 antagonist. Candesartan is an orally active lipophilic drug and possesses rapid oral absorption. It causes a reduction in blood pressure and is used in the treatment of hypertension. It is also used in the treatment of congestive heart failure and given as prophylaxis to reduce the severity and duration of migraine. Candesartan cilexetil, a prodrug of Candesartan, is available in the market under the trade names Atacand, Amias. Candesartan cilexetil is rapidly converted to candesartan, its active metabolite, during absorption from the gastrointestinal tract. Candesartan confers blood pressure lowering effects by antagonizing the hypertensive effects of angiotensin II via the RAAS (renin–angiotensin–aldosterone system). RAAS is a homeostatic mechanism for regulating hemodynamics, water, and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering the cardiovascular structure. Angiotensin II binds to two receptors: type-1 angiotensin II receptor (AT1) and type-2 angiotensin II receptor (AT2). Candesartan selectively blocks the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. This inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in an overall decrease in blood pressure. Candesartan is greater than 10,000 times more selective for AT1 than AT2.

CNS Activity

Curator's Comment: Candesartan crosses the blood-brain barrier poorly.

Originator

Curator's Comment: TCV-116 # Takeda, Osaka, Japan

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ATACAND

Approved Use

Candesartan Cilexetil Tablets are an angiotensin II receptor blocker (ARB) indicated for: •Treatment of hypertension in adults and children 1 to < 17 years of age (1.1). •Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and children 1 to < 17 years of age. It may be used alone or in combination with other antihypertensive agents. 1.2 Heart Failure Candesartan cilexetil tablets is indicated for the treatment of heart failure (NYHA class II-IV) in adults with left ventricular systolic dysfunction (ejection fraction ≤ 40%) to reduce cardiovascular death and to reduce heart failure hospitalizations [see CLINICAL STUDIES (14.2)

Launch Date

1998
Primary
ATACAND

Approved Use

Candesartan Cilexetil Tablets are an angiotensin II receptor blocker (ARB) indicated for: •Treatment of hypertension in adults and children 1 to < 17 years of age (1.1). •Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and children 1 to < 17 years of age. It may be used alone or in combination with other antihypertensive agents. 1.2 Heart Failure Candesartan cilexetil tablets is indicated for the treatment of heart failure (NYHA class II-IV) in adults with left ventricular systolic dysfunction (ejection fraction ≤ 40%) to reduce cardiovascular death and to reduce heart failure hospitalizations [see CLINICAL STUDIES (14.2)

Launch Date

1998
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
92 ng/mL
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
61 ng/mL
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
79 ng/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
55 ng/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1152 ng × h/mL
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
509 ng × h/mL
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1359 ng × h/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
485 ng × h/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15.7 h
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.1 h
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12 h
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6.7 h
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
unknown, unknown
CANDESARTAN CILEXETIL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
16 mg 1 times / day steady, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Co-administed with::
amlodipine(10 mg/day)
Sources:
unhealthy, 41 years
n = 1
Health Status: unhealthy
Age Group: 41 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Hepatitis...
AEs leading to
discontinuation/dose reduction:
Hepatitis (acute, 1 patient)
Sources:
32 mg 1 times / day steady, oral
Highest studied dose
Dose: 32 mg, 1 times / day
Route: oral
Route: steady
Dose: 32 mg, 1 times / day
Sources:
unhealthy, 59 years
n = 6
Health Status: unhealthy
Condition: Type 2 Diabetes
Age Group: 59 years
Population Size: 6
Sources:
23 mg 1 times / day steady, oral (mean)
Recommended
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
unhealthy, 67 years
n = 207
Health Status: unhealthy
Condition: heart failure
Age Group: 67 years
Sex: M+F
Population Size: 207
Sources:
Disc. AE: Hypotension, Hyperkalemia...
AEs leading to
discontinuation/dose reduction:
Hypotension (4.1%)
Hyperkalemia (2.4%)
Sources:
16 mg 1 times / day steady, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy
Other AEs: Disorder fetal...
2 mg 1 times / day steady, oral
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 2350
Health Status: unhealthy
Population Size: 2350
Sources:
Disc. AE: Headache, Dizziness...
AEs leading to
discontinuation/dose reduction:
Headache (0.6%)
Dizziness (0.3%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hepatitis acute, 1 patient
Disc. AE
16 mg 1 times / day steady, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Co-administed with::
amlodipine(10 mg/day)
Sources:
unhealthy, 41 years
n = 1
Health Status: unhealthy
Age Group: 41 years
Sex: F
Population Size: 1
Sources:
Hyperkalemia 2.4%
Disc. AE
23 mg 1 times / day steady, oral (mean)
Recommended
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
unhealthy, 67 years
n = 207
Health Status: unhealthy
Condition: heart failure
Age Group: 67 years
Sex: M+F
Population Size: 207
Sources:
Hypotension 4.1%
Disc. AE
23 mg 1 times / day steady, oral (mean)
Recommended
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
unhealthy, 67 years
n = 207
Health Status: unhealthy
Condition: heart failure
Age Group: 67 years
Sex: M+F
Population Size: 207
Sources:
Disorder fetal
16 mg 1 times / day steady, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy
Dizziness 0.3%
Disc. AE
2 mg 1 times / day steady, oral
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 2350
Health Status: unhealthy
Population Size: 2350
Sources:
Headache 0.6%
Disc. AE
2 mg 1 times / day steady, oral
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 2350
Health Status: unhealthy
Population Size: 2350
Sources:
PubMed

PubMed

TitleDatePubMed
Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
1999 Feb
Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells.
1999 Feb 19
Effect of beta(2)-adrenoceptor activation and angiotensin II on tumour necrosis factor and interleukin 6 gene transcription in the rat renal resident macrophage cells.
1999 Oct
The mechanism of action of angiotensin II is dependent on direct activation of vascular smooth muscle carbonic anhydrase I.
2000
[Angiotensin I receptor blockers for heart failure].
2001
The comparative pharmacology of angiotensin II receptor antagonists.
2001
The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.
2001
Efficacy and tolerability of angiotensin II type 1 receptor antagonists in dialysis patients using AN69 dialysis membranes.
2001
Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes.
2001 Apr
Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
2001 Apr
Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis.
2001 Apr
Angiotensin blockade inhibits increased JNKs, AP-1 and NF- kappa B DNA-binding activities in myocardial infarcted rats.
2001 Apr
Protective effect of agiotensin II type I receptor antagonist, CV-11974, on ischemia and reperfusion injury of the liver.
2001 Apr 27
Role of nNOS in regulation of renal function in angiotensin II-induced hypertension.
2001 Aug
Candesartan cilexetil reduces graft arteriosclerosis in aortic transplantation model in rat.
2001 Feb
[Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy].
2001 Feb
Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension.
2001 Feb
Mechanisms underlying renoprotection during renin-angiotensin system blockade.
2001 Feb
Alterations of the renin-angiotensin system at the RVLM of transgenic rats with low brain angiotensinogen.
2001 Feb
Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats.
2001 Feb
A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.
2001 Feb 1
Role of local renin-angiotensin system in warm ischemia and reperfusion injury of the liver.
2001 Feb-Mar
New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure.
2001 Jan
Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study.
2001 Jan-Feb
Cardioprotection with angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor antagonist is not abolished by nitric oxide synthase inhibitor in ischemia-reperfused rabbit hearts.
2001 Jul
The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats.
2001 Jul
Activation of angiotensin II subtype 2 receptor induces catecholamine release in an extracellular Ca(2+)-dependent manner through a decrease of cyclic guanosine 3',5'-monophosphate production in cultured porcine adrenal medullary chromaffin Cells.
2001 Jul
Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction.
2001 Jul
Angiotensin II activates the GFAT promoter in mesangial cells.
2001 Jul
Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators.
2001 Jun
Coronary hemodynamic and ventricular responses to angiotensin type 1 receptor inhibition in SHR: interaction with angiotensin type 2 receptors.
2001 Jun
Mildly oxidized low-density lipoprotein acts synergistically with angiotensin II in inducing vascular smooth muscle cell proliferation.
2001 Jun
Effects of TCV-116 on expression of NOS and adrenomedullin in failing heart of Dahl salt-sensitive rats.
2001 Jun
Antihypertensive effects of losartan and candesartan.
2001 Mar
Lithium intoxication after administration of AT1 blockers.
2001 Mar
Can angiotensin II receptor blockers be used in patients who have developed a cough or angioedema as a result of taking an ACE inhibitor?
2001 Mar
Perceived benefit after participating in positive or negative/neutral heart failure trials: the patients' perspective.
2001 Mar
Effects of converting enzyme inhibitors on renal P-450 metabolism of arachidonic acid.
2001 Mar
Combination treatment effective option for hypertensive, diabetic patients with microalbuminuria.
2001 Mar 20
An angiotensin II type 1 receptor blocker, candesartan, increases myocardial apoptosis in rats with acute ischemia-reperfusion.
2001 May
A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy.
2001 May
Role of cardiac ATP-sensitive K+ channels induced by angiotensin II type 1 receptor antagonist on metabolism, contraction and relaxation in ischemia-reperfused rabbit heart.
2001 May
[Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
2001 May 11
Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis.
2001 May 17
Angiotensin-II-receptor inhibitors in pregnancy.
2001 May 19
Effects of angiotensin II type 1 receptor antagonist (candesartan) in preventing fatal ventricular arrhythmias in dogs during acute myocardial ischemia and reperfusion.
2001 Nov
Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure.
2001 Oct
pK(a) determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry.
2001 Oct
ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts.
2001 Oct 12
Peripheral administration of an angiotensin II AT(1) receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation Stress.
2001 Sep
Patents

Sample Use Guides

Adult Hypertension: 2 DOSAGE AND ADMINISTRATION 2.1 Adult Hypertension The usual recommended starting dose of ATACAND (candesartan cilexetil) is 16 mg once daily when it is used as monotherapy in patients who are not volume depleted. ATACAND can be administered once or twice daily with total daily doses ranging from 8 mg to 32 mg. Pediatric Hypertension 1 to < 17 Years of Age: Children 1 to < 6 years of age: The dose range is 0.05 to 0.4 mg/kg per day. The recommended starting dose is 0.20 mg/kg (oral suspension). Children 6 to < 17 years of age: For those less than 50 kg, the dose range is 2 to 16 mg per day. The recommended starting dose is 4 to 8 mg. For those greater than 50 kg, the dose range is 4 to 32 mg per day. The recommended starting dose is 8 to 16 mg. Adult Heart Failure: The recommended initial dose for treating heart failure is 4 mg once daily. The target dose is 32 mg once daily, which is achieved by doubling the dose at approximately 2-week intervals, as tolerated by the patient.
Route of Administration: Oral
Primary cultures of human retinal endothelial cells (EC) were candesartan treatment (1μg/ml).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:16:03 GMT 2023
Edited
by admin
on Fri Dec 15 16:16:03 GMT 2023
Record UNII
R85M2X0D68
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CANDESARTAN CILEXETIL
USAN  
Official Name English
ATACAND
Brand Name English
CANDESARTAN CILEXETIL [VANDF]
Common Name English
CANDESARTAN 1-(((CYCLOHEXYLOXY)CARBONYL)OXY)ETHYL ESTER
MI  
Common Name English
CANDESARTAN CILEXETIL [USP-RS]
Common Name English
CANDESARTAN CILEXETIL [MART.]
Common Name English
TCV-116
Code English
1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID, 2-ETHOXY-1-((2'-(1H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-, 1-(((CYCLOHEXYLOXY)CARBONYL)OXY)ETHYL ESTER, (±)-
Common Name English
CANDESARTAN CILEXETIL [USAN]
Common Name English
NSC-758697
Code English
CANDESARTAN CILEXETIL [ORANGE BOOK]
Common Name English
CANDESARTAN 1-(((CYCLOHEXYLOXY)CARBONYL)OXY)ETHYL ESTER [MI]
Common Name English
CANDESARTAN CILEXETIL [EP MONOGRAPH]
Common Name English
CANDESARTAN CILEXETIL [USP MONOGRAPH]
Common Name English
(±)-1-HYDROXYETHYL 2-ETHOXY-1-(P-(O-1H-TETRAZOL-5-YLPHENYL)BENZYL)-7-BENZIMIDAZOLECARBOXYLATE, CYCLOHEXYL CARBONATE (ESTER)
Common Name English
Candesartan cilexetil [WHO-DD]
Common Name English
CANDESARTAN CILEXETIL [JAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66930
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
Code System Code Type Description
NSC
758697
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY
RS_ITEM_NUM
1087803
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY
MERCK INDEX
m3012
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY Merck Index
DAILYMED
R85M2X0D68
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY
DRUG CENTRAL
475
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY
DRUG BANK
DB00796
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY
NCI_THESAURUS
C28903
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY
MESH
C077793
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY
FDA UNII
R85M2X0D68
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY
ChEMBL
CHEMBL1014
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY
SMS_ID
100000091533
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY
CAS
145040-37-5
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY
RXCUI
135481
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY RxNorm
EPA CompTox
DTXSID5020239
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY
USAN
JJ-7
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY
PUBCHEM
2540
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY
EVMPD
SUB13222MIG
Created by admin on Fri Dec 15 16:16:03 GMT 2023 , Edited by admin on Fri Dec 15 16:16:03 GMT 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
IMPURITY -> PARENT
For the calculation of content, multiply the peak area by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
for the calculation of content, multiply the peak area by 0.7.
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
For the calculation of content, multiply the peak area by 1.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY